Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.
As filed with the Securities and Exchange Commission on February 10, 2026
Registration No. 333-292085
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 3
TO
FORM S-1
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
AIM ImmunoTech Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 2836 | 52-0845822 | ||
| (State
or other jurisdiction of incorporation or organization) |
(Primary
Standard Industrial Classification Code Number) |
(I.R.S.
Employer Identification Number) |
2117 SW Highway 484
Ocala FL 34473
(352) 448-7797
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Thomas K. Equels
Chief Executive Officer
AIM ImmunoTech Inc.
2117 SW Highway 484
Ocala FL 34473
(352) 448-7797
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Richard Feiner, Esq. Silverman, Shin & Schneider PLLC 88 Pine Street, 22nd Floor New York, NY 10005 (646) 822-1170 |
Barry I. Grossman, Esq. Matthew Bernstein, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas, 11th Floor New York, NY 10105 (212) 370-1300 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
This Amendment to the Registration Statement on Form S-1 (File No. 333-292085) is being filed as an “exhibits-only” filing solely to amend Item 16(a) of Part II thereof. Accordingly, this Amendment consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature page to the Registration Statement, and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted. Capitalized terms used and not otherwise defined in this Amendment have the meanings given them in the complete Registration Statement, the most recent version of which was filed on January 29, 2026.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution
The following is a statement of estimated expenses in connection with the issuance and distribution of the securities being registered, excluding dealer-manager fees. All expenses incurred with respect to the registration of the common stock will be borne by us. All amounts are estimates except the SEC registration fee and the FINRA filing fee.
| Item | Amount to be Paid | |||
| SEC registration fee | $ | 4,971.60 | ||
| FINRA filing fee | $ | 5,900.00 | ||
| Legal fees and expenses | $ | 120,000.00 | ||
| Accounting fees and expenses | 100,000.00 | |||
| Subscription Agent, Information Agent and Warrant Agent Fees and Expenses | 38,500.00 | |||
| Miscellaneous expenses | 7,862.00 | |||
| Total | $ | 272,262.00 | ||
Item 14. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law (the “DGCL”) inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Similar indemnity is authorized for such persons against expenses (including attorneys’ fees) actually and reasonably incurred in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard of conduct.
Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the Securities Act.
Section 102(b)(7) of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit.
Article Ninth of our Amended and Restated Certificate of Incorporation provides that we shall indemnify to the extent permitted by Delaware law any person whom it may indemnify thereunder, including directors, officers, employees and agents. Such indemnification (other than an order by a court) shall be made by us only upon a determination that indemnification is proper in the circumstances because the individual met the applicable standard of conduct. Advances for such indemnification may be made pending such determination. In addition, the Registrant’s Amended and Restated Certificate of Incorporation eliminates, to the extent permitted by Delaware law, personal liability of directors to the Registrant and its stockholders for monetary damages for breach of fiduciary duty as directors.
The foregoing discussion of our amended and restated certificate of incorporation and Delaware law is not intended to be exhaustive and is qualified in its entirety by such certificate of incorporation or law.
Insofar as the foregoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
| II-1 |
Item 15. Recent Sales of Unregistered Securities.
| Cost Basis Per Share of | ||||||||||||
Common Stock Post Split | Common Stock Indirect-Post Split | Common Stock- Post Split | ||||||||||
| Nancy Bryan | $ | 179.41 | — | 2,918 | ||||||||
| 3/21/2024 | $ | 39.00 | — | 384 | ||||||||
| 12/2/2024 | $ | 23.00 | — | 226 | ||||||||
| 12/13/2024 | $ | 21.30 | — | 245 | ||||||||
| 12/31/2024 | $ | 19.80 | — | 263 | ||||||||
| 1/15/2015 | $ | 19.00 | — | 274 | ||||||||
| 1/31/2025 | $ | 20.19 | — | 258 | ||||||||
| 2/14/2025 | $ | 12.02 | — | 433 | ||||||||
| 2/28/2025 | $ | 13.50 | — | 386 | ||||||||
| 3/14/2025 | $ | 11.60 | — | 449 | ||||||||
| David Chemerow | $ | 25.10 | — | 641 | ||||||||
| 2/28/2025 | $ | 13.50 | — | 193 | ||||||||
| 3/14/2025 | $ | 11.60 | — | 448 | ||||||||
| Thomas Equels | $ | 2,525.20 | — | 35,872 | ||||||||
| 4/25/2022 | $ | 102.00 | — | 490 | ||||||||
| 7/18/2022 | $ | 76.00 | — | 328 | ||||||||
| 1/3/2023 | $ | 31.00 | — | 1,612 | ||||||||
| 7/17/2023 | $ | 59.00 | — | 169 | ||||||||
| 8/24/2023 | $ | 66.70 | — | 149 | ||||||||
| 8/25/2023 | $ | 66.90 | — | 82 | ||||||||
| 9/29/2023 | $ | 44.10 | — | 226 | ||||||||
| 11/27/2023 | $ | 44.30 | — | 338 | ||||||||
| 3/15/2024 | $ | 33.00 | — | 757 | ||||||||
| 5/6/2024 | $ | 40.50 | — | 617 | ||||||||
| 8/12/2024 | $ | 26.50 | — | 3,773 | ||||||||
| 9/11/2024 | $ | 32.00 | — | 3,125 | ||||||||
| 9/13/2024 | $ | 30.80 | — | 200 | ||||||||
| 9/16/2024 | $ | 30.30 | — | 50 | ||||||||
| 11/20/2024 | $ | 114.83 | — | 1,451 | ||||||||
| 11/21/2024 | $ | 21.17 | — | 200 | ||||||||
| 12/19/2024 | $ | 20.60 | — | 227 | ||||||||
| 3/4/2025 | $ | 23.50 | — | 1,273 | ||||||||
| 3/5/2025 | $ | 13.46 | — | 500 | ||||||||
| 4/4/2025 | $ | 6.30 | — | 410 | ||||||||
| 4/21/2025 | $ | 2.54 | — | 19,685 | ||||||||
| 6/12/2025 | $ | 870.00 | — | 103 | ||||||||
| 6/13/2025 | $ | 769.70 | — | 107 | ||||||||
| Ted Kellner | $ | 37,205 | ||||||||||
| $ | 17,510 | |||||||||||
| $ | 19,695 | |||||||||||
| William Mitchell | $ | 142.95 | — | 4,505 | ||||||||
| 12/2/2024 | $ | 23.00 | — | 227 | ||||||||
| 12/13/2024 | $ | 21.30 | — | 245 | ||||||||
| 12/31/2024 | $ | 19.80 | — | 263 | ||||||||
| 1/15/2025 | $ | 19.00 | — | 274 | ||||||||
| 1/31/2025 | $ | 20.19 | — | 258 | ||||||||
| 2/14/2025 | $ | 12.02 | — | 433 | ||||||||
| 2/28/2025 | $ | 13.50 | — | 38 | ||||||||
| 3/14/2025 | $ | 14.14 | — | 2,419 | ||||||||
| Peter Rodino | $ | 259.50 | — | 3,435 | ||||||||
| 4/25/2022 | $ | 102.00 | — | 49 | ||||||||
| 1/3/2023 | $ | 31.00 | — | 806 | ||||||||
| 3/15/2024 | $ | 33.00 | — | 379 | ||||||||
| 5/6/2024 | $ | 40.50 | — | 309 | ||||||||
| 8/12/2024 | $ | 26.50 | — | 1,887 | ||||||||
| 4/4/2025 | $ | 26.50 | — | 5 | ||||||||
| Grand Total | $ | 3,132.16 | 37,205 | 47,371 | ||||||||
The foregoing issuances were made pursuant to employment agreements, reductions in salaries and compensation for directors serving on committees.
The offers, sales and issuances of securities described above was deemed to be exempt from registration under the Securities Act in reliance on either Section 4(a)(2) in that they did not involve a public offering, or Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701.
| II-2 |
Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits
The following exhibits are being filed with this Registration Statement:
| II-3 |
| II-4 |
| II-5 |
| II-6 |
* Indicates management contract or compensatory plan or arrangement.
+ Schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
† A portion of this Exhibit has been omitted as it contains information that (i) is not material and (ii) would be competitively harmful if publicly disclosed.
| II-7 |
(b) Financial Statement Schedules
All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.
Item 17. Undertakings
| (a) | The undersigned registrant hereby undertakes: |
| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
| (i) | To include any prospectus required by section 10(a)(3) of the Securities Act; | |
| (ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and | |
| (iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
| Provided, however, that paragraphs (a)(1)(i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in this registration statement. |
| (2) | That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| (4) | That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
| (i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
| II-8 |
| (ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; | |
| (iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and | |
| (iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
| (b) | The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (c) | Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |
| (d) | The undersigned registrant hereby undertakes that: |
| (1) | For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and |
| (2) | For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| II-9 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ocala, Florida on February 10, 2026.
| AIM IMMUNOTECH INC. | ||
| By: | /s/ Thomas K. Equels | |
| Thomas K. Equels | ||
| Chief Executive Officer and President | ||
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated:
| SIGNATURE | TITLE | DATE | ||
| /s/ Thomas K. Equels | February 10, 2026 | |||
| Thomas K. Equels | Chief Executive Officer and Director | |||
| /s/ Robert Dickey IV | February 10, 2026 | |||
| Robert Dickey IV | Chief Financial Officer | |||
| /s/ Thomas K. Equels* | February 10, 2026 | |||
| William Mitchell | Director | |||
| /s/ Thomas K. Equels* | February 10, 2026 | |||
| Nancy Bryan | Director | |||
| /s/ Thomas K. Equels* | February 10, 2026 | |||
| David Chemerow | Director | |||
/s/ Thomas K. Equels* |
February 10, 2026 | |||
| Ted Kellner | Director |
| * | As attorney in fact. |
| II-10 |